Magnetic resonance imaging of multiple sclerosis: new insights linking pathology to clinical evolution
暂无分享,去创建一个
[1] F. Barkhof,et al. Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. , 1998, Journal of neurology, neurosurgery, and psychiatry.
[2] F. Barkhof,et al. Cortical lesions in multiple sclerosis. , 1999, Brain : a journal of neurology.
[3] J. Neale,et al. Immunohistochemical localization of N-acetylaspartate in rat brain. , 1991, Neuroreport.
[4] F. Barkhof,et al. Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.
[5] Guido Gerig,et al. Exploring the discrimination power of the time domain for segmentation and characterization of active lesions in serial MR data , 2000, Medical Image Anal..
[6] S. Reingold,et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.
[7] R. Rudick,et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.
[8] I. Vavasour,et al. A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain , 2000, Neurology.
[9] A. Thompson,et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. , 1998, Brain : a journal of neurology.
[10] P M Matthews,et al. Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis , 1991, Neurology.
[11] P M Matthews,et al. In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. , 1999, Brain : a journal of neurology.
[12] G S Francis,et al. Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. , 1999, AJNR. American journal of neuroradiology.
[13] J. Coyle,et al. N‐Acetyl‐Aspartyl‐Glutamate: Regional Levels in Rat Brain and the Effects of Brain Lesions as Determined by a New HPLC Method , 1984, Journal of neurochemistry.
[14] G J Barker,et al. Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters , 1996, Journal of magnetic resonance imaging : JMRI.
[15] B D Trapp,et al. Axonal pathology in multiple sclerosis: relationship to neurologic disability. , 1999, Current opinion in neurology.
[16] N. Evangelou,et al. Association of the APOE ε4 allele with disease activity in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.
[17] R. Sapolsky,et al. Stress, Glucocorticoids, and Damage to the Nervous System: The Current State of Confusion. , 1996, Stress.
[18] A. Meyer-Franke,et al. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture , 1995, Neuron.
[19] H. Adams,et al. Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI , 2000, Neurology.
[20] P. Matthews,et al. Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.
[21] J K Udupa,et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.
[22] Bruce D. Trapp,et al. Axonal pathology in myelin disorders , 1999, Journal of neurocytology.
[23] Virginia M. Y. Lee,et al. Formation of Compact Myelin Is Required for Maturation of the Axonal Cytoskeleton , 1999, The Journal of Neuroscience.
[24] G Scarlato,et al. Central nervous system trans‐synaptic effects of acute axonal injury: a 1h magnetic resonance spectroscopy study , 1995, Magnetic resonance in medicine.
[25] J. Cooper,et al. N‐ACETYL‐l‐ASPARTIC ACID CONTENT OF HUMAN NEURAL TUMOURS AND BOVINE PERIPHERAL NERVOUS TISSUES , 1972, Journal of neurochemistry.
[26] H. Tallan,et al. N-Acetyl-L-aspartic acid in brain. , 1956, The Journal of biological chemistry.
[27] P. Matthews,et al. Putting Magnetic Resonance Spectroscopy Studies in Context: Axonal Damage and Disability in Multiple Sclerosis , 1998, Seminars in neurology.
[28] F. Condé,et al. Early N-Acetylaspartate Depletion Is a Marker of Neuronal Dysfunction in Rats and Primates Chronically Treated with the Mitochondrial Toxin 3-Nitropropionic Acid , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[29] A J Thompson,et al. Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis , 1995, Neurology.
[30] G J Barker,et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. , 2000, Brain : a journal of neurology.
[31] M Rovaris,et al. Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.
[32] P M Matthews,et al. The motor cortex shows adaptive functional changes to brain injury from multiple sclerosis , 2000, Annals of neurology.
[33] G. B. Pike,et al. Relating axonal injury to functional recovery in MS , 2000, Neurology.
[34] J S Wolinsky,et al. Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis , 1998, Annals of neurology.
[35] F. Barkhof,et al. Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[36] G. Barker,et al. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis , 1999, Neurology.
[37] A J Thompson,et al. Clinical and Magnetic Resonance Imaging Predictors of Disability in Primary and Secondary Progressive Multiple Sclerosis , 1996, Multiple sclerosis.
[38] J. Simon. From enhancing lesions to brain atrophy in relapsing MS , 1999, Journal of Neuroimmunology.
[39] A Benazzouz,et al. Lysolecithin-induced demyelination in primates: preliminary in vivo study with MR and magnetization transfer. , 1995, AJNR. American journal of neuroradiology.
[40] R. Kinkel,et al. A Wallerian degeneration pattern in patients at risk for MS , 2000, Neurology.
[41] M. Palkovits,et al. Axonal changes in chronic demyelinated cervical spinal cord plaques. , 2000, Brain : a journal of neurology.
[42] C Confavreux,et al. Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.
[43] T. Patel,et al. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. , 1979, The Biochemical journal.
[44] Frederik Barkhof,et al. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS) , 1999, Multiple sclerosis.
[45] S Ropele,et al. Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.
[46] F. Barkhof,et al. Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis , 1998, Annals of neurology.
[47] G. Barker,et al. Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study , 1999, Journal of Neurology.
[48] G. Barker,et al. Correlation of magnetization transfer ration with clinical disability in multiple sclerosis , 1994, Annals of neurology.
[49] G. B. Pike,et al. Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images. , 2000, Radiology.
[50] P M Matthews,et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? , 1999, Brain : a journal of neurology.
[51] J A Frank,et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis , 1998, Annals of neurology.
[52] M Filippi,et al. Correlations between clinical and MRI involvement in multiple sclerosis: assessment using T1, T2 and MT histograms , 1999, Journal of the Neurological Sciences.
[53] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[54] D. Jeffery,et al. Cortical deficits in multiple sclerosis on the basis of subcortical lesions , 2000, Multiple sclerosis.
[55] O. Paulson,et al. Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate , 2000, Multiple sclerosis.
[56] M Noble,et al. Specific Expression of N‐Acetylaspartate in Neurons, Oligodendrocyte‐Type‐2 Astrocyte Progenitors, and Immature Oligodendrocytes In Vitro , 1992, Journal of neurochemistry.
[57] J K Udupa,et al. Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images--lack of correlation between changes in T2 lesion volume and clinical findings. , 1999, Radiology.
[58] R. Kikinis,et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage , 2000, Journal of Neuroimmunology.
[59] G J Barker,et al. Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study , 2000, Journal of neurology, neurosurgery, and psychiatry.
[60] G. Barker,et al. Spinal cord atrophy and disability in MS , 1998, Neurology.
[61] S. Kimura,et al. Acute transient pseudoatrophy of the brain accompanying measles infection , 2000, Brain and Development.
[62] P. Matthews,et al. Imaging of axonal damage in multiple sclerosis: Spatial distribution of magnetic resonance imaging lesions , 1997, Annals of neurology.
[63] K. Bhakoo,et al. In Vitro Expression of N‐Acetyl Aspartate by Oligodendrocytes , 2000, Journal of neurochemistry.
[64] G. Gunston,et al. Reversible cerebral shrinkage in kwashiorkor: an MRI study. , 1992, Archives of disease in childhood.
[65] G. Barker,et al. Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations , 2000, Journal of neurology, neurosurgery, and psychiatry.
[66] C. Matute. Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[67] F. Barkhof,et al. Magnetization transfer imaging of the spinal cord and the optic nerve in patients with multiple sclerosis. , 1999, Neurology.
[68] R B Banati,et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.
[69] G J Barker,et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. , 2000, Brain : a journal of neurology.
[70] J. Prineas,et al. The fine structure of chronically active multiple sclerosis plaques , 1978, Neurology.
[71] R. Rudick,et al. Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.
[72] H. Lassmann,et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. , 2000, The American journal of pathology.
[73] J. Coyle,et al. Neurochemical and Immunocytochemical Studies on the Distribution of N‐Acetyl‐Aspartylglutamate and N‐Acetyl‐Aspartate in Rat Spinal Cord and Some Peripheral Nervous Tissues , 1987, Journal of neurochemistry.
[74] P. Matthews,et al. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. , 2000, Brain : a journal of neurology.
[75] L D Blumhardt,et al. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis , 1999, Journal of neurology, neurosurgery, and psychiatry.
[76] Nikos Evangelou,et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis , 2000, Annals of neurology.
[77] M W Weiner,et al. A serial study of new MS lesions and the white matter from which they arise , 1998, Neurology.
[78] P M Matthews,et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. , 2000, Brain : a journal of neurology.
[79] J. Coyle,et al. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.
[80] P M Matthews,et al. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques , 1992, Annals of neurology.
[81] P M Matthews,et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.
[82] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[83] A. Thompson,et al. The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis , 2000 .